■临床研究能力和服务提供的全球不平等可以简单地通过一个国家或地区在临床试验注册数据库中注册的临床试验的比例来表示。在非洲注册的临床试验比例很低,只有0.02%,尽管该地区约占世界人口的15%。尽管大多数非洲国家面临经济挑战,近年来,它们显示出增长和变化的潜力。
我们对在肯尼亚进行的介入临床试验进行了案头审查,埃塞俄比亚,和尼日利亚在2015年至2023年5月之间。搜索是在临床试验存储库中进行的,和日记存储库。搜索的重点是干预临床试验。通过出版物和临床试验平台筛选提取数据。从出版物中提取的数据包括临床试验的类型,临床试验阶段,疾病,等。从报告中提取的数据包括:进行临床试验的挑战,能力建设努力,以及临床试验的影响。
■在肯尼亚确定的临床试验研究数量为113(28个为婴儿临床试验)。该研究确定了尼日利亚的97项临床试验,其中11项研究是关于婴儿临床试验的。在埃塞俄比亚,有28项临床试验,只有5项是婴儿临床试验。景观审查还扩大了这三个国家临床试验的能力和差距。在肯尼亚进行的临床试验中,最大的比例是伤害,职业病,中毒,30.5%(n=18),最小的比例是肾病,新生儿疾病,产科,和妇科。大多数婴儿临床试验是在感染和感染领域进行的,占33.3%(n=7)。这三个国家的临床试验所面临的挑战大多包括缺乏基础设施,缺乏人力资源,缺乏财政资源。
有必要绘制非洲研究人员在非洲进行的临床试验,以排除非洲非非洲研究人员进行的试验。应支持临床试验的机会并应对挑战。
UNASSIGNED: Global inequality in clinical research capacity and service delivery can be indicated simply by the proportion of clinical trials that a country or region has registered in clinical trial registry databases. The proportion of clinical trials registered in Africa is very low at 0.02%, even though the region accounts for approximately 15% of the world\'s population. Despite the economic challenges in most African countries, they have shown potential for growth and change in recent years.
UNASSIGNED: We conducted desk reviews on the interventional clinical trials done in Kenya, Ethiopia, and Nigeria between 2015 to May 2023. The search was done in clinical trials repositories, and journal repositories. The search focused on intervention clinical trials. Data was extracted by screening through the publications and clinical trial platforms. The data extracted from the publications included the type of clinical trial, clinical trial phase, diseases, etc. The data extracted from the reports included: challenges in conducting clinical trials, capacity-building efforts, and the impact of the clinical trial.
UNASSIGNED: The number of clinical trial studies identified in Kenya was 113 (28 were on infant clinical trials). The study identified 97 clinical trials in Nigeria, of which 11 studies were on infant clinical trials. In Ethiopia, there were 28 clinical trials and only five were on infant clinical trials. The landscape review also expanded to capacity and gaps in clinical trials in the three countries. The largest proportion of clinical trials carried out in Kenya was on injury, occupational disease, and poisoning, 30.5% (n = 18) and the smallest proportion was on kidney disease, neonatal disease, obstetrics, and gynecology. Most Infant clinical trials were carried out in the area of infections and infestations 33.3% (n = 7). Most of the challenges faced by clinical trials in the three countries include a lack of infrastructure, a lack of human resources, and a lack of financial resources.
UNASSIGNED: There is a need to map clinical trials done by African researchers based in Africa to exclude the trials done by non-African researchers based in Africa. Opportunities for clinical trials should be supported and challenges addressed.